ARW vs SAIL

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant concerns in profitability, leverage, and operating efficiency. Despite this, the company shows resilience through solid revenue growth (13% YoY), consistent earnings beats (25.62% average surprise over last 4 quarters), and a reasonable Debt/Equity ratio of 0.48. Valuation appears attractive relative to peers with a P/E of 13.08 versus sector average of 89.76 and a Price/Book under 1, though low margins and declining recent EPS growth (-0.8% QoQ) temper optimism. The stock trades below its Graham Number ($157.92) and intrinsic value estimate ($212.3), suggesting potential undervaluation, but weak profitability metrics and lack of Altman Z-Score data limit confidence in financial stability.

The company exhibits severe operational weakness as evidenced by a Piotroski F-Score of 2/9, placing it in the 'Weak' health category. While revenue growth remains strong at 22.7% and the balance sheet is debt-free, the company is struggling with significant negative profitability (ROE -42.94%). This fundamental instability is compounded by a 0/100 technical trend and aggressive insider selling by the CEO and CFO. Despite a 'buy' consensus from analysts, the deterministic data suggests a high-risk profile with poor internal health.